Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs

A Multi-centre, Single Armed, Open Labelled Trial to Study the Efficacy and Safety Profile of Repaglinide & Metformin Combination Therapy in Chinese Type 2 Diabetics

This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of repaglinide and metformin combination therapy in Chinese subjects with type 2 diabetes inadequately controlled with OAD (oral anti-diabetic drugs).

Inclusion Criteria:

• Type 2 diabetes for at least 12 weeks
• HbA1c: 8.0-10.0%
• Current treatment with OAD on monotheray or OAD on combination therapy
• Body mass index (BMI): 21.0-35.0 kg/m2

Exclusion Criteria:

• Known or suspected allergy to trial product(s) or related products
• Recurrent major hypoglycaemia as judged by the Investigator
• Uncontrolled hypertension
• Any other significant condition or concomitant disease such as endocrine, cardiac, neurological, malignant or other pancreatic disease as judged by the Investigator